Socazolimab

[1]An J, et al. Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study. Clin Cancer Res. 2022 Dec 1;28 (23) :5098-5106.|[2]Lu S, et al. 143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial[J]. Annals of Oncology, 2022, 33: S99.|[3]Li Y, et al. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC) : A multicenter, randomized, double-blind phase II study[J]. Annals of Oncology, 2022, 33: S1101.|[4]Duan R, et al. Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma[J]. 2022.|[5]Zhou Y, et al. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001. Clin Cancer Res. 2023 Feb 16;29 (4) :764-774.